---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-015168"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:45:48.673557+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# KALA BIO Q3 net loss $9.0M; cash $49.2M; Phase 2b topline due 2Q 2025

## Summary
- Net loss $9.0M ($1.93/share) in Q3 2024 vs $8.7M ($3.41) in Q3 2023.
- Cash $49.2M as of Sep 30, 2024; funding expected into Q4 2025; includes $3.2M from CIRM.
- R&D $5.2M, G&A $4.4M; operating loss $10.0M in Q3 2024.
- Phase 2b CHASE trial for PCED enrolling; topline data expected 2Q 2025; five sites in Argentina.
- Exploring KPI-012 for LSCD (est. 100k patients); preclinical KPI-014 for inherited retinal diseases.

## SEC filing metadata
- accession: 0001558370-24-015168
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000155837024015168/0001558370-24-015168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000155837024015168/kala-20241112x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-015168
- JSON: https://secwatch.observer/filing/0001558370-24-015168.json
- Plain text: https://secwatch.observer/filing/0001558370-24-015168.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.